The Claim
In obese mice on a high-fat diet, biliverdin treatment reduces adipose tissue expression of the proinflammatory cytokine TNF-α and the M1 macrophage marker Cd11c, but does not significantly alter M2 macrophage markers or adiponectin levels.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice fed a high-fat diet, biliverdin lowers the levels of TNF-α and Cd11c in fat tissue but does not change levels of M2 macrophage markers or adiponectin.
See the scientific wording
In obese mice on a high-fat diet, biliverdin treatment reduces adipose tissue expression of the proinflammatory cytokine TNF-α and the M1 macrophage marker Cd11c, but does not significantly alter M2 macrophage markers or adiponectin levels.
When biliverdin enters fat tissue, it turns into bilirubin, which blocks the production of harmful reactive molecules by stopping a key enzyme complex. This reduction in reactive molecules lowers inflammation signals in fat, causing immune cells called macrophages to switch from a pro-inflammatory state to a less active one. As a result, the fat tissue releases less of the inflammatory protein TNF-alpha and fewer M1 macrophage markers, while anti-inflammatory signals remain unchanged.
What the research says
1 studyStudy: Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines
In obese mice, giving biliverdin lowered harmful inflammation signals in fat tissue (TNF-α and Cd11c) but didn’t change the helpful signals (like adiponectin or M2 markers), just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.